TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-949-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions
What is Tcr2 Therapeutics' stock symbol?
Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."
How were Tcr2 Therapeutics' earnings last quarter?
Tcr2 Therapeutics Inc (NASDAQ:TCRR) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. View Tcr2 Therapeutics' Earnings History.
When is Tcr2 Therapeutics' next earnings date?
What price target have analysts set for TCRR?
6 brokerages have issued 1-year price targets for Tcr2 Therapeutics' shares. Their predictions range from $16.00 to $37.00. On average, they anticipate Tcr2 Therapeutics' stock price to reach $27.80 in the next year. This suggests a possible upside of 86.5% from the stock's current price. View Analyst Price Targets for Tcr2 Therapeutics.
What is the consensus analysts' recommendation for Tcr2 Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tcr2 Therapeutics.
Has Tcr2 Therapeutics been receiving favorable news coverage?
News stories about TCRR stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tcr2 Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Tcr2 Therapeutics.
Who are some of Tcr2 Therapeutics' key competitors?
Some companies that are related to Tcr2 Therapeutics include Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), AVITA MED LTD/S (RCEL), Rubius Therapeutics (RUBY) and Vericel (VCEL).
What other stocks do shareholders of Tcr2 Therapeutics own?
Who are Tcr2 Therapeutics' key executives?
Tcr2 Therapeutics' management team includes the folowing people:
- Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
- Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
- Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
- Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)
When did Tcr2 Therapeutics IPO?
(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.
How do I buy shares of Tcr2 Therapeutics?
Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tcr2 Therapeutics' stock price today?
One share of TCRR stock can currently be purchased for approximately $14.91.
How big of a company is Tcr2 Therapeutics?
Tcr2 Therapeutics has a market capitalization of $357.33 million. The company earns $-24,250,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.View Additional Information About Tcr2 Therapeutics.
What is Tcr2 Therapeutics' official website?
How can I contact Tcr2 Therapeutics?
Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]
MarketBeat Community Rating for Tcr2 Therapeutics (NASDAQ TCRR)
MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote "Outperform" if you believe TCRR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.
